{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:13:22Z","timestamp":1790766802396,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["206602"],"award-info":[{"award-number":["206602"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A range of studies globally demonstrate that the effectiveness of SARS-CoV-2 vaccines wane over time, but the total effect of anti-S antibody levels on risk of SARS-CoV-2 infection and whether this varies by vaccine type is not well understood. Here we show that anti-S levels peak three to four weeks following the second dose of vaccine and the geometric mean of the samples is nine fold higher for BNT162b2 than ChAdOx1. Increasing anti-S levels are associated with a reduced risk of SARS-CoV-2 infection (Hazard Ratio 0.85; 95%CIs: 0.79-0.92). We do not find evidence that this antibody relationship with risk of infection varies by second dose vaccine type (BNT162b2 vs. ChAdOx1). In keeping with our anti-S antibody data, we find that people vaccinated with ChAdOx1 had 1.64 times the odds (95% confidence interval 1.45-1.85) of a breakthrough infection compared to BNT162b2. We anticipate our findings to be useful in the estimation of the protective effect of anti-S levels on risk of infection due to Delta. Our findings provide evidence about the relationship between antibody levels and protection for different vaccines and will support decisions on optimising the timing of booster vaccinations and identifying individuals who should be prioritised for booster vaccination, including those who are older, clinically extremely vulnerable, or received ChAdOx1 as their primary course. Our finding that risk of infection by anti-S level does not interact with vaccine type, but that individuals vaccinated with ChAdOx1 were at higher risk of infection, provides additional support for the use of using anti-S levels for estimating vaccine efficacy.<\/jats:p>","DOI":"10.1038\/s41467-022-32265-5","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T14:02:46Z","timestamp":1660831366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-0816","authenticated-orcid":false,"given":"Robert W.","family":"Aldridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Yavlinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max T.","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumita","family":"Shrotri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalan M. D.","family":"Navaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Beale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isobel","family":"Braithwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0477-2767","authenticated-orcid":false,"given":"Jana","family":"Kovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Fragaszy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Lam Erica","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8486-5890","authenticated-orcid":false,"given":"Cyril","family":"Geismar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5207-2776","authenticated-orcid":false,"given":"Parth","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Rodger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"32265_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1377\/hlthaff.2021.00619","volume":"40","author":"S Gupta","year":"2021","unstructured":"Gupta, S. et al. Vaccinations against COVID-19 May Have Averted Up To 140,000 deaths in the United States. Health Aff. 40, 1465\u20131472 (2021).","journal-title":"Health Aff."},{"key":"32265_CR2","doi-asserted-by":"publisher","unstructured":"Haas, E. J. et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(21)00566-1 (2021).","DOI":"10.1016\/S1473-3099(21)00566-1"},{"key":"32265_CR3","unstructured":"UKHSA. COVID-19 vaccine surveillance report 30 September 2021 (week 39). https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1022238\/Vaccine_surveillance_report_-_week_39.pdf."},{"key":"32265_CR4","unstructured":"Coronavirus vaccine\u2014weekly summary of Yellow Card reporting. https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting (2022)."},{"key":"32265_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","volume":"398","author":"M Shrotri","year":"2021","unstructured":"Shrotri, M. et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 398, 385\u2013387 (2021).","journal-title":"Lancet"},{"key":"32265_CR6","doi-asserted-by":"publisher","unstructured":"Andrews, N. et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. bioRxiv https:\/\/doi.org\/10.1101\/2021.09.15.21263583 (2021).","DOI":"10.1101\/2021.09.15.21263583"},{"key":"32265_CR7","doi-asserted-by":"publisher","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy trial. medRxiv https:\/\/doi.org\/10.1101\/2021.08.09.21261290 (2021).","DOI":"10.1101\/2021.08.09.21261290"},{"key":"32265_CR8","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"key":"32265_CR9","doi-asserted-by":"publisher","unstructured":"Wei, J. et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-01721-6 (2022).","DOI":"10.1038\/s41591-022-01721-6"},{"key":"32265_CR10","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/EDE.0000000000001088","volume":"30","author":"JP Vandenbroucke","year":"2019","unstructured":"Vandenbroucke, J. P. & Pearce, N. Test-negative designs: differences and commonalities with other case-control studies with \u2018other patient\u2019 controls. Epidemiology 30, 838\u2013844 (2019).","journal-title":"Epidemiology"},{"key":"32265_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/aje\/kww064","volume":"184","author":"SG Sullivan","year":"2016","unstructured":"Sullivan, S. G., Tchetgen Tchetgen, E. J. & Cowling, B. J. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am. J. Epidemiol. 184, 345\u2013353 (2016).","journal-title":"Am. J. Epidemiol."},{"key":"32265_CR12","doi-asserted-by":"crossref","unstructured":"Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg. Health Eur. 100208 (2021).","DOI":"10.1016\/j.lanepe.2021.100208"},{"key":"32265_CR13","doi-asserted-by":"publisher","unstructured":"Thomas, S. J. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2110345 (2021).","DOI":"10.1056\/NEJMoa2110345"},{"key":"32265_CR14","doi-asserted-by":"publisher","unstructured":"Chemaitelly, H. et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2114114 (2021).","DOI":"10.1056\/NEJMoa2114114"},{"key":"32265_CR15","doi-asserted-by":"publisher","unstructured":"Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2114228 (2021).","DOI":"10.1056\/nejmoa2114228"},{"key":"32265_CR16","doi-asserted-by":"publisher","unstructured":"Israel, A. et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. medRxiv https:\/\/doi.org\/10.1101\/2021.08.03.21261496 (2021).","DOI":"10.1101\/2021.08.03.21261496"},{"key":"32265_CR17","doi-asserted-by":"publisher","unstructured":"Mizrahi, B. et al. Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine; Preliminary study. bioRxiv https:\/\/doi.org\/10.1101\/2021.07.29.21261317 (2021).","DOI":"10.1101\/2021.07.29.21261317"},{"key":"32265_CR18","doi-asserted-by":"publisher","unstructured":"Hulme, W. J. et al. Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study using OpenSAFELY. bioRxiv 2021.10.13.21264937 https:\/\/doi.org\/10.1101\/2021.10.13.21264937 (2021).","DOI":"10.1101\/2021.10.13.21264937"},{"key":"32265_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186\u2013193 (2022).","journal-title":"Nat. Immunol."},{"key":"32265_CR20","doi-asserted-by":"publisher","unstructured":"Wyllie, D. et al. SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: a prospective cohort study in keyworkers. MedRxiv https:\/\/doi.org\/10.1101\/2020.11.02.20222778 (2021).","DOI":"10.1101\/2020.11.02.20222778"},{"key":"32265_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639\u2013644 (2021).","journal-title":"Nature"},{"key":"32265_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21444-5","volume":"12","author":"AK Wheatley","year":"2021","unstructured":"Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162 (2021).","journal-title":"Nat. Commun."},{"key":"32265_CR23","doi-asserted-by":"crossref","unstructured":"Notarbartolo, S. et al. Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. Sci. Immunol. 6, eabg5021 (2021).","DOI":"10.1126\/sciimmunol.abg5021"},{"key":"32265_CR24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.immuni.2021.05.010","volume":"54","author":"L Bergamaschi","year":"2021","unstructured":"Bergamaschi, L. et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity 54, 1257\u20131275.e8 (2021).","journal-title":"Immunity"},{"key":"32265_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41590-021-01089-8","volume":"23","author":"AC Dowell","year":"2022","unstructured":"Dowell, A. C. et al. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nat. Immunol. 23, 40\u201349 (2022).","journal-title":"Nat. Immunol."},{"key":"32265_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","volume":"601","author":"L Swadling","year":"2022","unstructured":"Swadling, L. et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature 601, 110\u2013117 (2022).","journal-title":"Nature"},{"key":"32265_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/infdis\/jiab176","volume":"224","author":"R da Silva Antunes","year":"2021","unstructured":"da Silva Antunes, R. et al. Differential T-cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers. J. Infect. Dis. 224, 70\u201380 (2021).","journal-title":"J. Infect. Dis."},{"key":"32265_CR28","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","volume":"184","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220\u20134236.e13 (2021).","journal-title":"Cell"},{"key":"32265_CR29","doi-asserted-by":"publisher","unstructured":"Wilhelm, A. et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine Sera and monoclonal antibodies. bioRxiv https:\/\/doi.org\/10.1101\/2021.12.07.21267432 (2021).","DOI":"10.1101\/2021.12.07.21267432"},{"key":"32265_CR30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","volume":"28","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med. 28, 472\u2013476 (2022).","journal-title":"Nat. Med."},{"key":"32265_CR31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","volume":"603","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature 603, 493\u2013496 (2022).","journal-title":"Nature"},{"key":"32265_CR32","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.xcrm.2021.100355","volume":"2","author":"A Tarke","year":"2021","unstructured":"Tarke, A. et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep. Med. 2, 100355 (2021).","journal-title":"Cell Rep. Med"},{"key":"32265_CR33","doi-asserted-by":"crossref","unstructured":"Woldemeskel, B. A., Garliss, C. C. & Blankson, J. N. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J. Clin. Investig. 131, e149335 (2021).","DOI":"10.1172\/JCI149335"},{"key":"32265_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMc2119358","volume":"386","author":"I Nemet","year":"2022","unstructured":"Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med. 386, 492\u2013494 (2022).","journal-title":"N. Engl. J. Med."},{"key":"32265_CR35","doi-asserted-by":"publisher","unstructured":"Hayward, A. et al. Risk factors, symptom reporting, healthcare-seeking behaviour and adherence to public health guidance: protocol for Virus Watch, a prospective community cohort study. bioRxiv https:\/\/doi.org\/10.1101\/2020.12.15.20248254 (2020).","DOI":"10.1101\/2020.12.15.20248254"},{"key":"32265_CR36","unstructured":"Elecsys\u00ae Anti-SARS-CoV-2. https:\/\/diagnostics.roche.com\/gb\/en\/products\/params\/elecsys-anti-sars-cov-2.html (2022)."},{"key":"32265_CR37","unstructured":"Ainsworth, M. The National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect. Dis. 20, 1390 (2020)."},{"key":"32265_CR38","unstructured":"UK Health Security Agency. Guidance for people previously considered clinically extremely vulnerable from COVID-19. https:\/\/www.gov.uk\/government\/publications\/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19\/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19 (2020)."},{"key":"32265_CR39","unstructured":"Department of Health and Social Care. Priority groups for coronavirus (COVID-19) vaccination: advice from the JCVI. https:\/\/www.gov.uk\/government\/publications\/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020 (2020)."},{"key":"32265_CR40","unstructured":"Therneau, T. A package for survival analysis in R. https:\/\/cran.r-project.org\/web\/packages\/survival\/vignettes\/survival.pdf (2022)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32265-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:35:42Z","timestamp":1669296942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32265-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32265"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32265-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.05.21265968","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ACH serves on the UK New and Emerging Respiratory Virus Threats Advisory Group. A.M.J. is Chair of the Committee for Strategic Coordination for Health of the Public Research. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4869"}}